Thromboxane synthesis inhibitors and receptor antagonists.
The biochemical, functional and clinical consequences of thromboxane (TX) A2 synthesis inhibition and receptor antagonism are reviewed, with emphasis on human studies in health and disease. Both platelet and glomerular TXA2 synthesis and action are discussed as potential targets for cyclooxygenase inhibitors, TX-synthase inhibitors and TXA2-receptor antagonists. While Aspirin remains the reference standard for new agents aimed at suppressing TXA2-dependent platelet activation, both synthase inhibitors and receptor antagonists might have a unique therapeutic potential in affecting TXA2-dependent loss of renal function.
Patrono
C
C
Department of Pharmacology, Catholic University School of Medicine, Rome, Italy.
D016861:Cyclooxygenase Inhibitors; D006801:Humans; D011982:Receptors, Prostaglandin / Q000037:antagonists & inhibitors*; D017482:Receptors, Thromboxane; D013928:Thromboxane A2 / Q000096:biosynthesis*; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors
D016861:Cyclooxygenase Inhibitors; D011982:Receptors, Prostaglandin; D017482:Receptors, Thromboxane; D013928:Thromboxane A2; D013930:Thromboxane-A Synthase